Advertisement

The Clinical and Financial Implications of Immediate or Deferred Treatment in Patients with Advanced Prostatic Cancer

  • Philip H. Smith
Conference paper
Part of the ESO Monographs book series (ESO MONOGRAPHS)

Abstract

Cancer of the prostate may be diagnosed because of symptoms of outflow obstruction, the effect of the local tumour on surrounding organs including the bladder (haematuria) and rectum (constipation or a feeling of fullness), by extension to the peritoneum producing discomfort, or by symptoms from metastases (occult cancer). It may come to light coincidentally following a prostatectomy for what was thought to have been benign disease (latent cancer) and is increasingly being diagnosed in Western Europe and the United States following routine health screening. Once diagnosed, the management will be determined by the stage of the disease and the therapeutic inclination of the surgeon.

Keywords

Prostatic Cancer Medroxyprogesterone Acetate Cyproterone Acetate Estramustine Phosphate Prostatic Capsule 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Pavone-Macaluso M et al: Comparison of diethylstilbestrol cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomised Phase ill trial of the European Organisation for Research and Treatment of Cancer Urological Group. J Urol 1986 (136):624–631PubMedGoogle Scholar
  2. 2.
    Smith PH et al: A comparison of the effect of diethylstilbestrol with low dose estramustin phosphate in the treatment of advanced prostatic cancer: final analysis of a phase III trial of the European Organisation for Research and Treatment of Cancer. J Urol 1986 (136):619–623PubMedGoogle Scholar
  3. 3.
    Veterans Administration Co-operative Urological Research Group: Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 1967 (124):1011–1017Google Scholar
  4. 4.
    Andersson L et al: Estramustine versus conventional estrogenic hormones in the initial treatment of highly or moderately differentiated prostatic carcinoma: a randomised study. Scand J Urol Nephrol 1980 (55, Suppl):143–145Google Scholar
  5. 5.
    Murphy GP, Huben RP, Priore R: Results of another trial of chemotherapy with and without hormones in patients with newly diagnosed metastatic prostate cancer. Urology 1986 (28):36PubMedCrossRefGoogle Scholar
  6. 6.
    De Voogt et al: Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organisation for Research and Treatment of Cancer trials 30761 and 30762. J Urol 1986 (135/2):303–307PubMedGoogle Scholar
  7. 7.
    Klotz LH et al: Intermittent endocrine therapy for advanced prostate cancer. Cancer 1986 (58):2546–2550PubMedCrossRefGoogle Scholar
  8. 8.
    Kirk D: Trials and tribulations in prostate cancer. Br J Urol 1987 (59):375–379PubMedCrossRefGoogle Scholar
  9. 9.
    Scott WW: Panel discussion on some aspects of urological endocrinology. In: North Central Section of the American Urological Association Postgraduate Seminar. Burger, Minneapolis, p 211. Cited by Thompson GJ: Long term control of prostatic cancer. Surg Clin North Am 1958 (39):963–971Google Scholar
  10. 10.
    Cockburn AG: Hormonal therapy: the benefits of postponed initiation. Urology 1984 (24):24–26PubMedGoogle Scholar
  11. 11.
    Paulson DF, Hodge GB Jr, Hinshaw W, and the Uro-Oncology Research Group: Radiation therapy versus delayed androgen deprivation for stage C carcinoma of the prostate. J Urol 1984 (131):901–902PubMedGoogle Scholar
  12. 12.
    Paulson DF: Multi modal therapy of prostatic cancer. J Urol 1981 (17):53Google Scholar
  13. 13.
    Newling DWW et al: The natural history of prostatic cancer - the argument for a no treatment policy. In: Pavone- Macaluso M, Smith PH and Bagshaw MA (eds) Testicular Cancer and other tumors of the Genito-Urinary Tract. Alan R Liss, New York 1985 pp 443–448Google Scholar
  14. 14.
    Parker MC et al: Is delayed treatment justified in carcinoma of the prostate? Br J Urol 1985 (57):724–728PubMedCrossRefGoogle Scholar
  15. 15.
    Handley RC et al: Deferred treatment for prostatic cancer. Br J Urol 1987 (in press)Google Scholar
  16. 16.
    Fair WR: Hormonal therapy of advanced prostatic cancer. J Urol 1986 (136):653–654PubMedGoogle Scholar
  17. 17.
    Byar DP: VACURG studies of post-prostatectomy survival. Scand J Urol Nephrol 1980 (55, Suppl):113–116Google Scholar
  18. 18.
    Byar DP: Review of the Veterans Administration Studies of cancer of the prostate and new results concerning treatment of stage I and II tumours. In: Pavone-Macaluso M, Smith PH and Edsmyr F (eds) Bladder Tumors and other Topics in Urological Oncology. Plenum, New York 1979 pp 471–492Google Scholar
  19. 19.
    Paulson DF: Treatment of locally confined prostatic cancer: radiotherapy versus surgery; limits of curability. In: Kurth KH, Debruyne FMJ, Schröder FJ, Splinter TAW and Wagener TDJ (eds) Progress and Controversies in Oncological Urology. Alan R Liss, New York 1984 pp 483–492Google Scholar
  20. 20.
    Stamey TA: Monographs in Urology 1985 (6):105Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • Philip H. Smith
    • 1
  1. 1.Department of UrologySt. James’s University HospitalLeedsU.K.

Personalised recommendations